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BACKGROUND
1Department of Internal Medicine, 2Department of Cardiology, Lehigh Valley Health Network, Allentown, Pennsylvania
•  Chronic Chagas Cardiomyopathy (CCC), a sequela of persistent 
Trypansoma cruzi parasitemia, is the most common form of 
dilated cardiomyopathy in Latin America. Up to 7 million people 
worldwide are affected, although a significant majority of those 
affected are in Latin America.1
•  Relevance: Over 300,000 people in the USA are infected with 
Chagas disease qualifying it as 1 of 5 “Neglected Parasitic 
Infections (NPIs)” by the CDC.2
•  There are 3 distinct phases of Chagas heart disease: 
acute, latent, and chronic. During the first two phases 
patients are usually asymptomatic without physical signs, 
EKG abnormalities, or radiographic evidence of cardiac 
involvement. However, by the time patients present with 
symptoms and signs of heart failure, they are subsequently 
diagnosed with Chronic Chagas Dilated Cardiomyopathy.3
•  Importance: Up to 30% of chronically Chagas-infected people 
can develop cardiac alterations leading to deadly arrhythmias 
such as Sick Sinus Syndrome (SSS).1
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CASE PRESENTATION
•  A 57 year old female from El Salvador with no past 
medical history presented from an outside hospital with 
lightheadedness. She denied chest pain or shortness 
of breath. Physical exam demonstrated jugular venous 
distention and abdominojugular reflux. Initial studies 
demonstrated sinus bradycardia with a 4.4s pause on EKG, 
negative troponins, and cardiomegaly on chest x-ray.
RESULTS
•  Negative: TSH, Lyme, 5-HIAA, ANA, CMV IgG/IgM, Parvovirus 
IgG/IgM, HIV, and TB.
•  Chagas: IgM negative, IgG positive 7.21.
•  2D Echo: Severely reduced left ventricular systolic 
function, global hypokinesis with LVEF 25%, enlarged right 
ventricular size with reduced right ventricular systolic 
function and high right atrial pressures, and severe diastolic 
dysfunction.
•  Left heart catheterization: Non-obstructive coronary 
circulation.
•  Right heart catheterization: Fick cardiac index 1.54 L/min 
with Fick cardiac output 2.62 L/min.
•  Permanent Pacemaker (PPM) implantation indication: SSS with 
documented symptomatic bradycardia including symptoms 
from frequent sinus pauses (ACCF/AHA/HRS Class I, Level C).5
•  Implantable cardioverter defibrillator (ICD) implantation, 
primary prophylaxis indication: Chagas cardiomyopathy (ACC/
AHA/HRS Class IIa, Level C).5
•  Per the 2015 BENEFIT trial and the CDC recommendation: 
There is no significant reduction in cardiac complications or 
death with anti-trypanosomal therapy in those with Chronic 
Chagas Cardiomyopathy. Angiotensin-converting-enzyme 
inhibitors (ACEi’s) or angiotensin receptor blockers (ARBs), 
beta blockers, and diuretics are the mainstay of therapy.2,4
•  Looking forward: Vector control. Public health initiative: 
educating at-risk communities about preventive measures: 
thoroughly cooking food, sleeping in sheltered housing, 
wearing protective clothing, and using bug repellent on the 
skin when outdoors.1,2
INTERVENTIONS
•  Transvenous pacemaker followed by pacemaker-ICD. 
•  Beta blocker and Angiotensin-converting-enzyme inhibitor.
•  No anti-trypanosomal therapy per 2015 BENEFIT Trial.
DISCUSSION
Sinus bradycardia with 4.4 second pause followed by a generation and conduction of 
a junctional escape beat.
